Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
FST-344
A follistatin isoform studied in myostatin inhibition and muscle-growth research.
- Half-life (approx.)
- ~hours to days (approx., isoform-dependent)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 1 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
FST-344 (follistatin 344) is a follistatin isoform that binds activin and myostatin ligands, studied for muscle-hypertrophy endpoints in rodent models. Gene-therapy and protein-administration studies examine lean-mass changes under controlled conditions. Follistatin isoform neutralizes myostatin-family ligands — distinct from ACE-031 decoy mechanism.
Structure & identity
Follistatin-344 isoform — glycoprotein
- Sequence / structure
- Follistatin-344 isoform — glycoprotein
Mechanism
Follistatin isoform neutralizes myostatin and activin, promoting muscle-growth signaling. Activin A and myostatin neutralization promotes muscle-growth signaling in hypertrophy models.
Studies & clinical programs
Myostatin knockout comparisons
Published research models
- Peer-reviewed literature documents endpoints under Myostatin knockout comparisons experimental designs.
Muscle hypertrophy rodent models
Published research models
- Peer-reviewed literature documents endpoints under Muscle hypertrophy rodent models experimental designs.
Research models in literature
- Myostatin knockout comparisons
- Muscle hypertrophy rodent models
Literature highlights
- Follistatin isoform neutralizes myostatin and activin in muscle-hypertrophy rodent studies.
- Lean-mass endpoints compared with myostatin-knockout and ACE-031-class approaches.
- Glycoprotein handling and storage distinct from short synthetic peptides.
Combination research notes
Muscle research compares FST-344 with IGF-1 LR3 and ACE-031-class approaches.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Refrigerated (2–8 °C); do not shake vial | Recombinant proteins and glycoproteins require gentle handling; inspect cake integrity and store upright per IU potency literature. |
| Reconstituted | Manufacturer diluent or bacteriostatic water, refrigerated | Swirl gently until dissolved — never shake vigorously; refrigerated stability is often shorter than small peptides (days to ~2 weeks). |
| Working aliquots | Frozen (−20 °C) in protein-grade tubes | Aliquot by IU or mg immediately after reconstitution; label concentration and avoid foam formation during draw. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 1 | 1 | 1000.0 | 10 | 25 | 50 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; concentration varies by published formulation.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance